Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade

Open access
Pacifici, Roberto·1998·Endocrinology

Abstract

Postmenopausal osteoporosis is a heterogeneous disorder characterized by a progressive loss of bone tissue that begins after natural or surgical menopause and leads to fracture within 15–20 yr from the cessation of the ovarian function. Although suboptimal skeletal development (“low peak bone mass”) and age-related bone loss may be contributing factors, a hormone-dependent increase in bone resorption and accelerated loss of bone mass in the first 5 or 10 yr after the menopause appears to be the main pathogenetic factor. During the past decade, considerable evidence has accumulated that suggests that estrogen prevents bone loss by blocking the production of proinflammatory cytokines by bone marrow and bone cells (1, 2). The main consequence of increased cytokine production in the bone microenvironment is an expansion of the osteoclastic pool due to increased osteoclast (OC) formation and elongation of their life-span (3). In addition, enhanced cytokine production results in increased activity of mature OCs and in increased osteoblastic activity. The latter compensates, in part, the consequences of increased bone formation on bone mass. Cytokines exert their regulatory effects on bone turnover by stimulating both the secretory and proliferative activities of mature cells. However, they also condition the differentiation of immature cells leading to the emergence of new phenotypes that favor osteoclastogenesis. Examples of this phenomenon are the differentiation of stromal cells precursors in “high osteoclastogenic” stromal cells, as a result of the increased bone marrow levels of interleukin (IL)-1 and tumor necrosis factor (TNF) induced by estrogen deficiency (4), and the differentiation of cells of the monocytic lineage into osteoclasts in response to factors produced by stromal cells such as IL-6, IL-11 (2), and macrophage colony-stimulating factor (M-CSF) (5). Among the cytokines now known to be regulated by estrogen are IL-1, IL-6, and TNF (1, 2). IL-1 and TNF are the most powerful locally produced stimulators of bone resorption and are well recognized inhibitors of bone formation. These cytokines promote bone resorption in vitro and cause bone loss and hypercalcemia when infused in vivo. IL-1 and TNF activate mature osteoclasts indirectly via a primary effect on osteoblasts and inhibit osteoclast apoptosis. In addition, they markedly enhance osteoclast formation by stimulating the proliferation of osteoclast precursor both directly and by enhancing the pro-osteoclastogenic activity of stromal cells. IL-1 and TNF are also powerful inducers of other cytokines that regulate the differentiation of osteoclast precursor cells into mature osteoclasts, such as IL-6, M-CSF, and granulocyte M-CSF. Therefore, with respect to osteoclastogenesis, IL-1 and TNF should be regarded as “upstream” cytokines necessary for inducing the secretion of “downstream” factors that stimulate hematopoietic osteoclast precursors. This cascade mechanism ensures that small changes in IL-1 and TNF levels results in large changes in osteoclast production. A specific competitive inhibitor of IL-1, known as IL-1ra, has also been identified (6). IL-1ra, which has a 26% amino acid sequence homology with IL-1β, binds to cells expressing primarily the 87-kD type I IL-1 receptor with nearly the same affinity as IL-1 and competes with either IL-1α or IL-1β on these cells without detectable IL-1 agonist effects. The type I IL-1 receptor is expressed in T cells, tissue macrophages, endothelial cells, and bone cells. IL-1ra also binds, although with a lower affinity, to the type II IL-1 receptor, which is expressed mainly in blood neutrophils and B cells. Because the binding of 5 molecules of IL-1 per cell is sufficient to induce a full biological response, a 50% IL-1 inhibition in bone cells requires amounts of IL-1ra up to 100 times in excess of the amounts of IL-1α or IL-1β present. IL-6 is a potent osteoclastogenic factor that exerts its effects via a cell surface receptor that consists of a ligand binding chain (IL-6R) and a signal transducing chain known as gp130. When bound to soluble IL-6R, IL-6 stimulates the early stages of osteoclastogenesis in human and murine cultures, presumably by forming a complex with gp130 expressed on either stromal cell or osteoblasts (7). IL-6 increases in vitro bone resorption in systems rich in osteoclast precursors, such as the mouse fetal metacarpal assay (8), whereas it has no effect in organ cultures where more mature cells predominate, such as murine fetal radii (9). This suggests that IL-6 is more potent in increasing the formation of osteoclasts from hemopoietic precursors than in activating mature osteoclasts. Over the past decades, numerous reports have been published demonstrating that natural or surgical menopause increases blood, bone marrow, and monocytic levels of IL-1, IL-6, TNF, and the related factors IL-1ra and IL-6R (1, 2). In vitro studies have also documented the ability of estrogen treat

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endo.139.6.6087

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 194

Metadata

Authors
Pacifici, R.
Venue
Endocrinology
Published
1998-06
Volume
139
Issue
6
Pages
2659-2661
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2116281705
Cited by
194
References
2
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade. https://app.cochat.ai/papers/10.1210/endo.139.6.6087
The paper
Pacifici, R. (1998). Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis—The Second Decade. Endocrinology. https://doi.org/10.1210/endo.139.6.6087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.